As of 2026-10-16, the Relative Valuation of 10X Genomics Inc (TXG) is (19.82) USD. This relative valuation is based on P/E multiples. With the latest stock price at 72.39 USD, the upside of 10X Genomics Inc based on Relative Valuation is -127.4%.
The range of the Relative Valuation is (20.62) - (18.84) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 34.8x - 37.1x | 36.6x |
| Forward P/E multiples | 26.7x - 31.8x | 30.4x |
| Fair Price | (20.62) - (18.84) | (19.82) |
| Upside | -128.5% - -126.0% | -127.4% |
| Date | P/E |
| 2026-10-15 | -122.34 |
| 2026-10-14 | -123.54 |
| 2026-10-13 | -121.32 |
| 2026-10-12 | -127.07 |
| 2026-10-09 | -136.30 |
| 2026-10-08 | -130.60 |
| 2026-10-07 | -128.61 |
| 2026-10-06 | -136.31 |
| 2026-10-05 | -165.18 |
| 2026-10-02 | -158.01 |
| 2026-10-01 | -150.00 |
| 2026-09-30 | -152.71 |
| 2026-09-29 | -152.17 |
| 2026-09-28 | -149.56 |
| 2026-09-25 | -144.85 |
| 2026-09-24 | -142.14 |
| 2026-09-23 | -127.80 |
| 2026-09-22 | -136.38 |
| 2026-09-21 | -133.68 |
| 2026-09-18 | -129.45 |
| 2026-09-17 | -130.08 |
| 2026-09-16 | -122.83 |
| 2026-09-15 | -125.72 |
| 2026-09-14 | -118.48 |
| 2026-09-11 | -115.92 |
| 2026-09-10 | -112.18 |
| 2026-09-09 | -113.72 |
| 2026-09-08 | -110.86 |
| 2026-09-04 | -105.88 |
| 2026-09-03 | -106.84 |
| 2026-09-02 | -104.19 |
| 2026-09-01 | -101.37 |
| 2026-08-31 | -105.54 |
| 2026-08-28 | -104.00 |
| 2026-08-27 | -109.60 |
| 2026-08-26 | -108.60 |
| 2026-08-25 | -109.38 |
| 2026-08-24 | -107.82 |
| 2026-08-21 | -110.05 |
| 2026-08-20 | -107.94 |
| 2026-08-19 | -105.10 |
| 2026-08-18 | -94.01 |
| 2026-08-17 | -98.00 |
| 2026-08-14 | -94.79 |
| 2026-08-13 | -98.27 |
| 2026-08-12 | -97.60 |
| 2026-08-11 | -98.83 |
| 2026-08-10 | -98.98 |
| 2026-08-07 | -87.93 |
| 2026-08-06 | -77.06 |